Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MBRX
MOLECULIN BIOTECH, INC.
NASDAQ
$0.65
▼ DOWN 5.63% (-0.04)

KEY STATISTICS

Market Cap$3.47 M
52w High$15.75
52w Low$0.16
Dividend Yield—
Frequency—
P/E-0.04
Volume612.68K
Shares Out.5.34M

COMPANY

LEADERSHIP

Walter V. Klemp
CHIEF EXECUTIVE
Walter V. Klemp

COMPENSATION 2026

Salary$565,000
Stock Awards$0
Incentive Plan Pay$426,750
All Other Comp.$29,315
Total$1,345,958

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 2, 2016
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
17

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2025-12-01Reverse1:25
2024-03-22Reverse1:15
2021-02-01Reverse1:6

PRICE

$0.65 ▼ DOWN 5.63% (−$0.04)
OVERLAYS
$0.64$0.66$0.68$0.709:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.65

About Moleculin Biotech, Inc.

https://www.moleculin.com ↗

Moleculin Biotech, a Houston-based clinical-stage company, develops drug candidates like Annamycin and WP1066 targeting resistant tumors, viruses, and cancers, with ongoing Phase 1/2 trials for AML, brain tumors, and COVID-19.

INDUSTRY

Biotechnology

A PRODUCT MOLECULIN BIOTECH, INC. IS KNOWN FOR

Annamycin
Annamycin

Annamycin, Moleculin Biotech’s lead clinical-stage drug, is a next-generation anthracycline in Phase 3 trials for relapsed/refractory AML and STS lung metastases.

COMPETITORS

COMPETITOR
BMY COMPARE
JAZZ COMPARE
KURA COMPARE
PFE COMPARE
SNDX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 42.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
14.11%
HOLDERS
30
TOP 12 OF 30 · RANKED BY POSITION SIZE
Vanguard Group Inc
239.9K sh · $127.16K
Geode Capital Management, LLC
208.2K sh · $110.35K
Hrt Financial LP
115.2K sh · $61K
Lpl Financial LLC
58.1K sh · $30.78K
Ieq Capital, LLC
36.4K sh · $19.27K
Wealth Dimensions Group, Ltd.
20.0K sh · $10.6K
Rockefeller Capital Management L.P.
14.5K sh · $7.69K
Cambridge Investment Research Advisors, Inc.
12.8K sh · $7K
Goldman Sachs Group Inc
12.8K sh · $6.76K
Blackrock Inc.
12.5K sh · $43.91K
Blackrock, Inc.
12.4K sh · $6.56K
Truist Financial Corp
10.5K sh · $5.57K

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score3

INSIDER TRADES

★
OFFICER: CHIEF SCIENCE OFFICER
PICKER DONALD H
Purchase · 520.0K shares
2026-08-03
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
KLEMP WALTER V
Purchase · 533.3K shares
2026-08-03
★
OFFICER: CHIEF SCIENCE OFFICER
PICKER DONALD H
Purchase · 173.3K shares
2026-08-03
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
KLEMP WALTER V
Purchase · 1.6M shares
2026-08-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
APLM$26.60COMPARE
BLRX$2.60COMPARE
LNAI$2.37COMPARE
AIMD$1.41COMPARE
ICU$3.09COMPARE
CTXR$0.60COMPARE